The Securities and Exchange Commission has charged an adviser to Rockville-based Human Genome Sciences Inc. (NASDAQ: HGSI) with insider trading.
The SEC claims that French doctor and researcher Yves M. Benhamou, an adviser to HGS for the development of its Hepatitis C drug Albuferon, illegally tipped off a hedge fund manager with negative results of a clinical trial before the results were made public.
Read more: Human Genome Sciences adviser accused of insider trading | Washington Business Journal